Rheumatoid Arthritis
12
Companies
18
Drug Programs
6
Phase 3
0
Upcoming PDUFAs
Eli Lilly and Company
cDMARD
Astellas Pharma
CZP
Coherus Oncology, Inc.
Etanercept
Gilead Sciences, Inc.
MTX
Amgen Inc.
Etanercept Liquid
Sanofi
Sulfasalazine
AnaptysBio, Inc.
Rosnilimab
Aclaris Therapeutics, Inc.
ATI-450
Galapagos NV
GLPG0634
Ionis Pharmaceuticals, Inc.
ISIS 104838
Ionis Pharmaceuticals, Inc.
ISIS CRP Rx or Placebo
Galapagos NV
Placebo
Galapagos NV
GLPG0259 oral capsule
Vertex Pharmaceuticals Incorporated
VX-702
Vertex Pharmaceuticals Incorporated
VX-509
Aclaris Therapeutics, Inc.
ATI-450 50 mg oral tablet BID
Galapagos NV
GLPG3970
XBiotech Inc.
Natrunix
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company | cDMARD | Phase 3 | — | — | — |
| ALPMY Astellas Pharma | CZP | Phase 3 | — | — | — |
| CHRS Coherus Oncology, Inc. | Etanercept | Phase 3 | — | — | — |
| GILD Gilead Sciences, Inc. | MTX | Phase 3 | — | — | — |
| AMGN Amgen Inc. | Etanercept Liquid | Phase 3 | — | — | — |
| SNY Sanofi | Sulfasalazine | Phase 3 | — | — | — |
| ANAB AnaptysBio, Inc. | Rosnilimab | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0634 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS 104838 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS CRP Rx or Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | Placebo | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG0259 oral capsule | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-702 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-509 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-450 50 mg oral tablet BID | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG3970 | Phase 2 | — | — | — |
| XBIT XBiotech Inc. | Natrunix | Phase 2 | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.